Monte Income Tax Expense from 2010 to 2025

GLUE Stock  USD 5.42  0.25  4.41%   
Monte Rosa's Income Tax Expense is increasing over the years with very volatile fluctuation. Overall, Income Tax Expense is expected to go to about 2.7 M this year. During the period from 2010 to 2025 Monte Rosa Income Tax Expense annual values regression line had geometric mean of  484,513 and mean square error of 2.4 T. View All Fundamentals
 
Income Tax Expense  
First Reported
2020-03-31
Previous Quarter
71 K
Current Value
2.2 M
Quarterly Volatility
873.6 K
 
Covid
Check Monte Rosa financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Monte Rosa's main balance sheet or income statement drivers, such as Net Interest Income of 11.1 M, Depreciation And Amortization of 3.9 M or Interest Expense of 4.5 M, as well as many indicators such as Price To Sales Ratio of 5.42, Dividend Yield of 0.0 or PTB Ratio of 2.42. Monte financial statements analysis is a perfect complement when working with Monte Rosa Valuation or Volatility modules.
  
Check out the analysis of Monte Rosa Correlation against competitors.

Latest Monte Rosa's Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Monte Rosa Therapeutics over the last few years. It is Monte Rosa's Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Monte Rosa's overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Very volatile
   Income Tax Expense   
       Timeline  

Monte Income Tax Expense Regression Statistics

Arithmetic Mean166,656
Geometric Mean484,513
Coefficient Of Variation896.74
Mean Deviation779,039
Median277,000
Standard Deviation1,494,470
Sample Variance2.2T
Range6.6M
R-Value0.06
Mean Square Error2.4T
R-Squared0
Significance0.82
Slope18,929
Total Sum of Squares33.5T

Monte Income Tax Expense History

20252.7 M
20242.6 M
2023338 K
2022-3.9 M
2021-2 M
2020189 K

About Monte Rosa Financial Statements

Monte Rosa stakeholders use historical fundamental indicators, such as Monte Rosa's Income Tax Expense, to determine how well the company is positioned to perform in the future. Although Monte Rosa investors may analyze each financial statement separately, they are all interrelated. For example, changes in Monte Rosa's assets and liabilities are reflected in the revenues and expenses on Monte Rosa's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Monte Rosa Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense2.6 M2.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:
Check out the analysis of Monte Rosa Correlation against competitors.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.98)
Revenue Per Share
1.023
Return On Assets
(0.14)
Return On Equity
(0.36)
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.